To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Mia Weiss; Vanessa Eulo; Brian A. Van Tine

doi:10.1158/1078-0432.CCR-23-2787

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Mia Weiss, Vanessa Eulo, Brian A. Van Tine

Research output: Contribution to journal › Article › peer-review

Abstract

Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient’s response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.

Original language	English
Pages (from-to)	649-651
Number of pages	3
Journal	Clinical Cancer Research
Volume	30
Issue number	4
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-2787
State	Published - Feb 15 2024

Access to Document

10.1158/1078-0432.CCR-23-2787

Cite this

@article{1106fd8cf1174aeb9d0c4577352a169a,

title = "To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma",

abstract = "Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient{\textquoteright}s response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.",

author = "Mia Weiss and Vanessa Eulo and {Van Tine}, {Brian A.}",

note = "Publisher Copyright: C 2023 American Association for Cancer Research.",

year = "2024",

month = feb,

day = "15",

doi = "10.1158/1078-0432.CCR-23-2787",

language = "English",

volume = "30",

pages = "649--651",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "4",

}

TY - JOUR

T1 - To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

AU - Weiss, Mia

AU - Eulo, Vanessa

AU - Van Tine, Brian A.

N1 - Publisher Copyright: C 2023 American Association for Cancer Research.

PY - 2024/2/15

Y1 - 2024/2/15

N2 - Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient’s response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.

AB - Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient’s response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.

UR - http://www.scopus.com/inward/record.url?scp=85185226267&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-2787

DO - 10.1158/1078-0432.CCR-23-2787

M3 - Article

C2 - 38064245

AN - SCOPUS:85185226267

SN - 1078-0432

VL - 30

SP - 649

EP - 651

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this